Effects Of Telbivudine Combined With Compound Qishu Decoction On Patients With Hepatitis B E Antigen-positive Chronic Hepatitis B

Objective:To evaluate the efficacy of telbivudine combined with compound qishu decoction (QS) versus telbivudine therapy on patients with HBeAg-positive chronic hepatitis B.Methods:104 treatment-naive CHB patients were assigned to two groups with cohort study:the telbivudine combined with QS treatment group and the telbivudine control group. Serum HBeAg, HBV DNA, hepatic and renal function, CD4 and CD8 were detected at different therapy time points.Results:In contrast to control group, there is a higher HBeAg negative conversion rate in therapy group at week 12,24 and 52 respectively(P>0.05). At week 52, there is no significant difference in the normalization of ALT levels (77.08% vs 75%), undetectable HBV DNA levels (68.75% vs 64.29%) and HBeAg negative serological conversion rate (25% vs 37.50%) (P>0.05).On the contrary, a statistically significant increase of serum CD4+T and CD8+T cell levels through therapeutic process in treatment group was observed (P<0.05). However, CD4+T and CD8+T remained unchanged in control group.Conclusion:Telbivudine combined with QS promoted HBeAg negative serological conversion possibly through enhancement of immune fuctions.